Corbus Pharmaceuticals Holdings (CRBP) : Traders are bullish on Corbus Pharmaceuticals Holdings (CRBP) as it has outperformed the S&P 500 by a wide margin of 96.96% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 36.58%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 37.31% in the last 1 week, and is up 92.97% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 54.08% and the 50-Day Moving Average is 97.24%.The 200 Day SMA reached 195.73% Corbus Pharmaceuticals Holdings, Inc. is up 143.69% in the last 3-month period. Year-to-Date the stock performance stands at 332.73%.
Corbus Pharmaceuticals Holdings (CRBP) has been rated by 3 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $8 and the lowest price target forecast is $6. The average forecast of all the analysts is $7.08 and the expected standard deviation is $0.88.
For the current week, the company shares have a recommendation consensus of Buy. Corbus Pharmaceuticals Holdings (NASDAQ:CRBP): The stock opened at $7.1 and touched an intraday high of $7.88 on Friday. During the day, the stock corrected to an intraday low of $6.77, however, the bulls stepped in and pushed the price higher to close in the green at $7.14 with a gain of 1.71% for the day. The total traded volume for the day was 4,258,403. The stock had closed at $7.14 in the previous trading session.
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, life-threating inflammatory-fibrotic diseases. The Companys lead product candidate, Resunab, is an oral anti-inflammatory drug that is being developed for the treatment of inflammatory disorders, such as cystic fibrosis (CF) and scleroderma. The Company has completed the Phase I safety studies for the treatment of scleroderma and cystic fibrosis. The Company has submitted an Investigational New Drug Application (INDA) to the United States Food and Drug Administration (FDA) for a Phase IIa double-blind placebo controlled clinical study evaluating Resunab in patients with diffuse scleroderma. Pre-clinical and Phase I clinical studies (123 subjects) have shown Resunab to have a favorable safety profile coupled with suitable potency in pre-clinical models of inflammation and fibrosis.